Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Kiniksa Pharmaceuticals International Plc's Business Segments
Kiniksa Pharmaceuticals International Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2025
Reportable Segments
1
Largest Segment
Pharmaceutical Segment
Total Revenue
$ 157
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2025
- Pharmaceutical Segment100%
Revenue by Reportable Segment - Q2 FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Pharmaceutical Segment | $ 157 | 100% |
Revenue by Product & Service Category - Q2 FY2025
- Product100%
- Collaboration0%
Revenue by Product & Service Category - Q2 FY2025
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 157 | 100% |
| Collaboration | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Kiniksa Pharmaceuticals International Plc
Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for patients with devastating diseases and unmet medical needs. The company was founded in 2015 and is based in Hamilton, Bermuda.
The company has a portfolio of product candidates targeting multiple indications, including autoimmunity, inflammation, and oncology. These product candidates are based on the company's expertise in immune and inflammatory pathways.
Kiniksa's lead product candidate is Rilonacept, a recombinant fusion protein that blocks interleukin-1 alpha and beta, which are cytokines that play a significant role in inflammation. Rilonacept is currently in Phase III clinical trials for the treatment of recurrent pericarditis, a rare autoinflammatory disease affecting the lining of the heart.
The company's other product candidates include KPL-716, a monoclonal antibody that targets the CD40 ligand, which is a critical mediator of inflammation in multiple autoimmune diseases. KPL-404 is another product candidate being developed for the treatment of prurigo nodularis, a chronic itch disorder.
Kiniksa Pharmaceuticals operates with a focus on research and development, seeking out new methodologies to develop new therapeutics. This includes collaborating with various research institutions and universities, as well as partnering with other biotechnology and pharmaceutical companies.
The company's management team consists of industry veterans with extensive experience in drug discovery, development, and commercialization. Furthermore, the company follows a well-defined set of values and principles, promoting ethical behavior and corporate social responsibility.
In summary, Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company that is committed to discovering and developing therapeutics for patients with unmet medical needs. With a strong pipeline of product candidates and a focus on research and development, the company has positioned itself as a leader in the biotechnology industry. Additionally, the company operates with a strong sense of corporate social responsibility, promoting ethical behavior and transparency in its operations.
The company has a portfolio of product candidates targeting multiple indications, including autoimmunity, inflammation, and oncology. These product candidates are based on the company's expertise in immune and inflammatory pathways.
Kiniksa's lead product candidate is Rilonacept, a recombinant fusion protein that blocks interleukin-1 alpha and beta, which are cytokines that play a significant role in inflammation. Rilonacept is currently in Phase III clinical trials for the treatment of recurrent pericarditis, a rare autoinflammatory disease affecting the lining of the heart.
The company's other product candidates include KPL-716, a monoclonal antibody that targets the CD40 ligand, which is a critical mediator of inflammation in multiple autoimmune diseases. KPL-404 is another product candidate being developed for the treatment of prurigo nodularis, a chronic itch disorder.
Kiniksa Pharmaceuticals operates with a focus on research and development, seeking out new methodologies to develop new therapeutics. This includes collaborating with various research institutions and universities, as well as partnering with other biotechnology and pharmaceutical companies.
The company's management team consists of industry veterans with extensive experience in drug discovery, development, and commercialization. Furthermore, the company follows a well-defined set of values and principles, promoting ethical behavior and corporate social responsibility.
In summary, Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company that is committed to discovering and developing therapeutics for patients with unmet medical needs. With a strong pipeline of product candidates and a focus on research and development, the company has positioned itself as a leader in the biotechnology industry. Additionally, the company operates with a strong sense of corporate social responsibility, promoting ethical behavior and transparency in its operations.
Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company that is dedicated to advancing therapies in the fields of immunology and inflammation. The company has developed a robust portfolio organized into various segments, each targeting distinct therapeutic areas. Below is a comprehensive overview of the segments, products, and services offered by Kiniksa Pharmaceuticals.
Segments:
1. Rare Disease:
Kiniksa Pharmaceuticals has made significant strides in the rare disease segment, focusing on conditions that often lack effective treatments due to their low prevalence. The company aims to leverage innovative therapeutic approaches to address unmet needs in this area. One of the key products in this segment is KPL-716, a promising investigational therapeutic aimed at treating immune thrombocytopenia. This condition involves a low platelet count and is often linked to autoimmune responses, making targeted treatment crucial for patients.
2. Autoimmune Disease:
Within the autoimmune disease segment, Kiniksa Pharmaceuticals is committed to developing and commercializing novel therapies. This segment addresses a wide range of autoimmune conditions, which can significantly impact patients quality of life. KPL-716 plays a dual role here, as it is also being evaluated for use in other autoimmune diseases such as lupus and rheumatoid arthritis. This highlights the drugs versatility and the companys dedication to finding effective solutions for multiple patient populations.
3. Neurological Disease:
The neurological disease segment seeks to address complex neurodegenerative disorders that affect millions of individuals worldwide. KPL-404, a kinase inhibitor, is a central figure in this endeavor, specifically targeting huntingtons disease—a progressive and debilitating disorder. The development of KPL-404 reflects Kiniksas focus on innovative therapies that can significantly alter the course of neurological diseases and improve patient outcomes.
Products:
1. KPL-404:
KPL-404 represents a cutting-edge approach in the treatment of neurodegenerative conditions. By inhibiting specific kinases that play a role in disease progression, KPL-404 aims to halt or slow down the progression of Huntingtons disease and potentially other related neurological disorders.
2. KPL-716:
As one of the flagship products, KPL-716 is a monoclonal antibody tailored for the treatment of autoimmune disorders. Its dual evaluation for immune thrombocytopenia and various autoimmune diseases reflects Kiniksas strategic vision of leveraging single product candidates to address different indications, thereby maximizing therapeutic innovations.
3. KPL-914:
Another notable product from Kiniksa is KPL-914, a nano-antibody designed to treat atopic dermatitis and associated allergic conditions. This platform technology stands to offer patients a less invasive and more effective treatment option, highlighting the companys focus on building a diverse portfolio that caters to multiple aspects of immune-related conditions.
Services:
1. Clinical Trials:
Kiniksa Pharmaceuticals actively engages in clinical trials as a core service to validate the efficacy and safety of its product candidates. The company has a dedicated team of researchers and experts responsible for designing trials, executing protocols, and analyzing data. This rigorous process ensures that Kiniksas therapies stand up to scientific scrutiny and regulatory standards.
2. Patient Support Programs:
Beyond product development, Kiniksa Pharmaceuticals emphasizes patient-centric care through robust support programs. These programs provide patients with critical resources, including education on their conditions, financial assistance options, and emotional support mechanisms. By fostering a supportive environment, Kiniksa reinforces its commitment to improving the overall patient experience, complimenting its therapeutic offerings.
3. Medical Education:
Kiniksa Pharmaceuticals is also invested in educating healthcare professionals about its products, therapeutic areas, and emerging research findings. Through a combination of online learning modules, live educational events, and informative resources, the company seeks to enhance the knowledge base of medical professionals, empowering them to make informed decisions about patient care.
In summary, Kiniksa Pharmaceuticals International Plc is actively engaged in a range of therapeutic areas with an emphasis on rare diseases, autoimmune conditions, and neurological disorders. The development and commercialization of innovative products like KPL-404, KPL-716, and KPL-914 demonstrate the companys commitment to advancing healthcare solutions, while its dedicated services support the needs of patients and healthcare providers alike.
Segments:
1. Rare Disease:
Kiniksa Pharmaceuticals has made significant strides in the rare disease segment, focusing on conditions that often lack effective treatments due to their low prevalence. The company aims to leverage innovative therapeutic approaches to address unmet needs in this area. One of the key products in this segment is KPL-716, a promising investigational therapeutic aimed at treating immune thrombocytopenia. This condition involves a low platelet count and is often linked to autoimmune responses, making targeted treatment crucial for patients.
2. Autoimmune Disease:
Within the autoimmune disease segment, Kiniksa Pharmaceuticals is committed to developing and commercializing novel therapies. This segment addresses a wide range of autoimmune conditions, which can significantly impact patients quality of life. KPL-716 plays a dual role here, as it is also being evaluated for use in other autoimmune diseases such as lupus and rheumatoid arthritis. This highlights the drugs versatility and the companys dedication to finding effective solutions for multiple patient populations.
3. Neurological Disease:
The neurological disease segment seeks to address complex neurodegenerative disorders that affect millions of individuals worldwide. KPL-404, a kinase inhibitor, is a central figure in this endeavor, specifically targeting huntingtons disease—a progressive and debilitating disorder. The development of KPL-404 reflects Kiniksas focus on innovative therapies that can significantly alter the course of neurological diseases and improve patient outcomes.
Products:
1. KPL-404:
KPL-404 represents a cutting-edge approach in the treatment of neurodegenerative conditions. By inhibiting specific kinases that play a role in disease progression, KPL-404 aims to halt or slow down the progression of Huntingtons disease and potentially other related neurological disorders.
2. KPL-716:
As one of the flagship products, KPL-716 is a monoclonal antibody tailored for the treatment of autoimmune disorders. Its dual evaluation for immune thrombocytopenia and various autoimmune diseases reflects Kiniksas strategic vision of leveraging single product candidates to address different indications, thereby maximizing therapeutic innovations.
3. KPL-914:
Another notable product from Kiniksa is KPL-914, a nano-antibody designed to treat atopic dermatitis and associated allergic conditions. This platform technology stands to offer patients a less invasive and more effective treatment option, highlighting the companys focus on building a diverse portfolio that caters to multiple aspects of immune-related conditions.
Services:
1. Clinical Trials:
Kiniksa Pharmaceuticals actively engages in clinical trials as a core service to validate the efficacy and safety of its product candidates. The company has a dedicated team of researchers and experts responsible for designing trials, executing protocols, and analyzing data. This rigorous process ensures that Kiniksas therapies stand up to scientific scrutiny and regulatory standards.
2. Patient Support Programs:
Beyond product development, Kiniksa Pharmaceuticals emphasizes patient-centric care through robust support programs. These programs provide patients with critical resources, including education on their conditions, financial assistance options, and emotional support mechanisms. By fostering a supportive environment, Kiniksa reinforces its commitment to improving the overall patient experience, complimenting its therapeutic offerings.
3. Medical Education:
Kiniksa Pharmaceuticals is also invested in educating healthcare professionals about its products, therapeutic areas, and emerging research findings. Through a combination of online learning modules, live educational events, and informative resources, the company seeks to enhance the knowledge base of medical professionals, empowering them to make informed decisions about patient care.
In summary, Kiniksa Pharmaceuticals International Plc is actively engaged in a range of therapeutic areas with an emphasis on rare diseases, autoimmune conditions, and neurological disorders. The development and commercialization of innovative products like KPL-404, KPL-716, and KPL-914 demonstrate the companys commitment to advancing healthcare solutions, while its dedicated services support the needs of patients and healthcare providers alike.